西班牙13,837人接种四种新冠疫苗第一剂后一周内副作用调查(ProVaVac调查研究)
2021年在西班牙瓦伦西亚地区对接种四种新冠疫苗(BNT162b2、mRNA-1273、ChAdOx1nCoV-19、JNJ-78436735)的人群进行调查,于接种后第1、3、7天收集自报副作用。14.35%未报告症状,45.20%仅轻度,24.89%中度,15.56%报告严重症状;女性、年轻、既往检测阳性、慢性病及非BNT162b2接种与副作用风险增加相关(p<0.001)。
要点
- 接种后一周内副作用常见但以轻度为主,频率在数日内下降。
- 15.56%报告严重症状,最常见为极度疲劳(7.0%)和恶心呕吐(7.1%)。
- 面瘫报告频率(0.4%)远高于产品特性摘要(SmPC)所列。
核心结论
- 真实世界中疫苗接种后副作用常见,但主要为轻度,且频率在数日后下降。
研究设计与样本
- 2021年4月19日至2021年10月6日在西班牙瓦伦西亚地区开展的调查研究,共纳入13,837名接种者,于接种后第1天、第3天和第7天收集数据。
主要发现
- 1,986名受访者(14.35%)未报告症状,6,254人(45.20%)仅报告轻度症状,3,444人(24.89%)报告至中度症状,2,153人(15.56%)报告严重症状。
- 报告严重症状者中,较常见的是极度疲劳(7.0%)和恶心或呕吐(7.1%)。
- 面瘫报告频率(0.4%)远高于各产品特性摘要(SmPC)所列频率。
- 女性、较年轻年龄、既往活动性感染诊断检测阳性、慢性病以及接种非BNT162b2疫苗与副作用风险增加相关(p < 0.001)。
临床怎么用
- 作者认为,向患者提供可靠的事前副作用信息可能改善结局并强化疫苗接种规划。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2021, four vaccines against Covid-19 (BNT162b2, mRNA-1273, ChAdOx1nCoV-19, and JNJ-78436735) were employed in the region of Valencia, Spain. We conducted a survey to identify real-world, self-reported frequency and severity of side effects during the week after vaccination. METHODS: Survey data was obtained from April 19, 2021, to October 6, 2021, at three different moments in time: day one, day three and day seven after vaccination. Answers were linked to individual-level, personal and clinical information. Respondents were stratified by the vaccine they received and reported effects were presented over time and stratified by severity. We compared our results per vaccine with the frequencies stated in each Summary of Product Characteristics (SmPC). We used binomial logistic models to identify associations between respondent characteristics and side effects. RESULTS: No symptoms were reported by 1,986 respondents (14.35 %), 6,254 informed exclusively mild symptoms (45.20 %), 3,444 up to moderate symptoms (24.89 %), and 2,153 people (15.56 %) notified also severe symptoms. Among the latter, the more frequent were extreme tiredness (7.0 %), and nausea or vomiting (7.1 %). The reported frequency of facial paralysis (0.4 %) was much higher than reflected in SmPCs. Female sex, younger age, previous positive Active Infection Diagnostic Test, chronicity, and vaccination with other than the BNT162b2 vaccine were associated to an increased risk of side effects (p < 0.001). CONCLUSIONS: Side effects after vaccination are common in the real-world. However, they are principally mild, and their frequency declines after a few days. Providing patients with dependable, beforehand information about side effects may improve outcomes and reinforce vaccination programs.
引用
- Sánchez-Saez F, Peiró S, Cuenca L, et al. Side effects during the week after first dose vaccination with four Covid-19 vaccines. Results of the ProVaVac Survey Study with 13,837 people in Spain. Vaccine. 2022. PMID: 36068110. doi:10.1016/j.vaccine.2022.08.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。